BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 16622265)

  • 1. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
    Zhu AX; Blaszkowsky LS; Ryan DP; Clark JW; Muzikansky A; Horgan K; Sheehan S; Hale KE; Enzinger PC; Bhargava P; Stuart K
    J Clin Oncol; 2006 Apr; 24(12):1898-903. PubMed ID: 16622265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
    Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
    Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
    Asnacios A; Fartoux L; Romano O; Tesmoingt C; Louafi S S; Mansoubakht T; Artru P; Poynard T; Rosmorduc O; Hebbar M; Taieb J
    Cancer; 2008 Jun; 112(12):2733-9. PubMed ID: 18412149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
    Louafi S; Boige V; Ducreux M; Bonyhay L; Mansourbakht T; de Baere T; Asnacios A; Hannoun L; Poynard T; Taïeb J
    Cancer; 2007 Apr; 109(7):1384-90. PubMed ID: 17330837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
    Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J
    Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
    Sun W; Sohal D; Haller DG; Mykulowycz K; Rosen M; Soulen MC; Caparro M; Teitelbaum UR; Giantonio B; O'Dwyer PJ; Shaked A; Reddy R; Olthoff K
    Cancer; 2011 Jul; 117(14):3187-92. PubMed ID: 21264839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.
    Fogelman D; Jafari M; Varadhachary GR; Xiong H; Bullock S; Ozer H; Lin E; Morris J; Cunningham P; Bennett B; Abbruzzese JL; Wolff RA
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1431-8. PubMed ID: 21479635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer.
    Lilenbaum R; Raez L; Tseng J; Seigel L; Davila E
    J Thorac Oncol; 2008 May; 3(5):511-5. PubMed ID: 18449004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
    Zhu AX; Meyerhardt JA; Blaszkowsky LS; Kambadakone AR; Muzikansky A; Zheng H; Clark JW; Abrams TA; Chan JA; Enzinger PC; Bhargava P; Kwak EL; Allen JN; Jain SR; Stuart K; Horgan K; Sheehan S; Fuchs CS; Ryan DP; Sahani DV
    Lancet Oncol; 2010 Jan; 11(1):48-54. PubMed ID: 19932054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin.
    Li S; Niu Z; Tian H; Zhang B; Wang F; Yi LH; Yu J
    Hepatogastroenterology; 2007; 54(73):218-23. PubMed ID: 17419264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.
    He SL; Shen J; Sun XJ; Zhu XJ; Liu LM; Dong JC
    World J Gastroenterol; 2013 Jul; 19(28):4552-8. PubMed ID: 23901232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.
    Patt YZ; Murad W; Fekrazad MH; Baron AD; Bansal P; Boumber Y; Steinberg K; Lee SJ; Bedrick E; Du R; Lee FC
    Cancer Med; 2017 Sep; 6(9):2042-2051. PubMed ID: 28801995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
    Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
    J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
    Hsu CH; Yang TS; Hsu C; Toh HC; Epstein RJ; Hsiao LT; Chen PJ; Lin ZZ; Chao TY; Cheng AL
    Br J Cancer; 2010 Mar; 102(6):981-6. PubMed ID: 20160718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.
    Heist RS; Fidias P; Huberman M; Ardman B; Sequist LV; Temel JS; Lynch TJ
    J Thorac Oncol; 2008 Oct; 3(10):1153-8. PubMed ID: 18827612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
    Corazzelli G; Capobianco G; Arcamone M; Ballerini PF; Iannitto E; Russo F; Frigeri F; Becchimanzi C; Marcacci G; De Chiara A; Pinto A
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):907-16. PubMed ID: 19219604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.
    Salimon M; Prieux-Klotz C; Tougeron D; Hautefeuille V; Caulet M; Gournay J; Matysiak-Budnik T; Bennouna J; Tiako Meyo M; Lecomte T; Zaanan A; Touchefeu Y
    Br J Cancer; 2018 Feb; 118(3):325-330. PubMed ID: 29169182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases.
    Ikeda Y; Takano M; Oda K; Kouta H; Goto T; Kudoh K; Sasaki N; Kita T; Kikuchi Y
    Int J Gynecol Cancer; 2013 Feb; 23(2):355-60. PubMed ID: 23358182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
    Jang JS; Lim HY; Hwang IG; Song HS; Yoo N; Yoon S; Kim YH; Park E; Byun JH; Lee MA; Oh SJ; Lee KH; Kim BS; Oh SC; Kim SY; Lee SJ
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):641-7. PubMed ID: 19652971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies.
    Patrikidou A; Sinapi I; Regnault H; Fayard F; Bouattour M; Fartoux L; Faivre S; Malka D; Ducreux M; Boige V
    Invest New Drugs; 2014 Oct; 32(5):1028-35. PubMed ID: 24748335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.